Dostarlimab vs Retifanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04655976 · Phase 2/3 · active, not recruiting

Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.

Next expected readout: January 2027 · NCT06879717 (registry estimate)

Reported efficacy

Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)

Result source: NCT04655976

Retifanlimab

Marketed by Incyte

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT04205812 · Phase 3 · completed

Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).

Next expected readout: December 2027 · NCT07219576 (registry estimate)

Reported efficacy

Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)

Result source: NCT04205812

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDostarlimabRetifanlimab
PFS, median4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
7.7 vs 5.5+2.2 vs placebon 391NCT04205812
OS, median11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
18.1 vs 13.4+4.7 vs placebon 391NCT04205812
ORR18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
51.7% vs 38.5%+13.2 vs placebon 391NCT04205812
Duration of response, median8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
12.7 vs 6.1+6.6 vs placebon 202NCT04205812

PFS, median

Dostarlimab
4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
Retifanlimab
7.7 vs 5.5+2.2 vs placebon 391NCT04205812

OS, median

Dostarlimab
11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
Retifanlimab
18.1 vs 13.4+4.7 vs placebon 391NCT04205812

ORR

Dostarlimab
18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
Retifanlimab
51.7% vs 38.5%+13.2 vs placebon 391NCT04205812

Duration of response, median

Dostarlimab
8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
Retifanlimab
12.7 vs 6.1+6.6 vs placebon 202NCT04205812
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dostarlimab: 3 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDostarlimabRetifanlimab
Dropout rate
25.6%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
21.6%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
100%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
—Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Serious AEs
33.8%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
42.7%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
58.3%Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
40.6%Retifanlimab + Chemotherapy
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
20.3%Retifanlimab Monotherapy
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
a
anaemia 34.8%
neutropenia 31.5%
fatigue 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 2 more results
anaemia 31.5%
fatigue 29.8%
diarrhoea 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
nausea 58.3%
diarrhoea 50%
fatigue 41.7%
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
anaemia 60.4% (placebo 56.8%)
decreased appetite 22.6% (placebo 13.2%)
neutrophil count decreased 21.6% (placebo 17.4%)
NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
aspartate aminotransferase increased 23.7% (placebo 22.1%)
anaemia 22% (placebo 56.8%)
alanine aminotransferase increased 15.3% (placebo 23.7%)
NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dostarlimab

Overall Survival 11.9 months
time to event · months
No placebo or comparator arm
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 9.1% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 21.5 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Disease Control 54.5% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
PFS 4.4 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Retifanlimab's landscape